Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

1/23/25 7:00:00 AM ET

Medical/Dental Instruments

Health Care

Get the next $GKOS alert in real time by email

Conference Call and Webcast Scheduled for 1:30 p.m. PT

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2024 financial results after the market close on Thursday, February 20, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on February 20, 2025.

A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay will be archived on the company's website following completion of the call.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose^® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250123829865/en/

Chris Lewis

Vice President, Investor Relations and Corporate Affairs

(949) 481-0510

[email protected]

Get the next $GKOS alert in real time by email

Recent Analyst Ratings for

$GKOS

Date	Price Target	Rating	Analyst
5/1/2025	$86.00	Overweight → Equal Weight	Wells Fargo
2/19/2025	$140.00 → $200.00	Neutral → Outperform	Mizuho
12/11/2024	$132.00 → $162.00	Neutral → Buy	Citigroup
12/6/2024	$182.00	Buy	UBS
12/2/2024	$120.00	Equal-Weight → Underweight	Morgan Stanley
7/10/2024	$132.00	Buy → Neutral	Citigroup
5/6/2024	$84.00 → $125.00	Hold → Buy	Jefferies
12/21/2023	$66.00 → $91.00	Neutral → Overweight	JP Morgan

More analyst ratings

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Chat with this insight

Recent Analyst Ratings for $GKOS

$GKOS Press Releases

Fastest customizable press release news feed in the world

Glaukos Announces First Quarter 2025 Financial Results

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

$GKOS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP & CHIEF FINANCIAL OFFICER Thurman Alex R. covered exercise/tax liability with 2,484 shares, decreasing direct ownership by 5% to 50,636 units (SEC Form 4)

CHAIRMAN & CEO Burns Thomas William covered exercise/tax liability with 7,957 shares, decreasing direct ownership by 5% to 145,602 units (SEC Form 4)

CHIEF DEVELOPMENT OFFICER Navratil Tomas covered exercise/tax liability with 994 shares, decreasing direct ownership by 1% to 81,604 units (SEC Form 4)

$GKOS FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

FDA Approval for IDOSE TR issued to GLAUKOS CORP

FDA Approval for TRAVOPROST issued to GLAUKOS CORP

$GKOS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

$GKOS Financials

Live finance-specific insights

Glaukos Announces First Quarter 2025 Financial Results

Glaukos to Release First Quarter 2025 Financial Results after Market Close on April 30

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

$GKOS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Glaukos downgraded by Wells Fargo with a new price target

Glaukos upgraded by Mizuho with a new price target

Glaukos upgraded by Citigroup with a new price target

$GKOS SEC Filings

SEC Form 10-Q filed by Glaukos Corporation

Glaukos Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Glaukos Corporation

$GKOS Leadership Updates

Live Leadership Updates

OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

Recent Analyst Ratings for
$GKOS

$GKOS
Press Releases

$GKOS
Insider Trading

$GKOS
FDA approvals

$GKOS
Large Ownership Changes

$GKOS
Financials

$GKOS
Analyst Ratings

$GKOS
SEC Filings

$GKOS
Leadership Updates